Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
US10508087B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 18, 2018 |
| Grant date | Dec 17, 2019 |
| Priority date | — |
| Expiry date | Mar 18, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel crystalline forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.